Skip to main content
Premium Trial:

Request an Annual Quote

NIH to Award $1.4M Per Year to Develop Integrative Data Analysis Tools for LINCS Program

Premium

The National Human Genome Research Institute and the National Heart, Lung, and Blood Institute plan to grant up to $1.4 million per year over the next two years to fund the development of computational tools for the Library of Integrated Network-based Cellular Signatures, or LINCS, program, according to a recent announcement from the National Institutes of Health.

According to the grant summary, the NIH is looking for “grant applications that would develop innovative computational tools and approaches for the integrative analysis of multiple types of data generated within the LINCS program.“

The program will fund four awards in fiscal year 2011 for up to two years at $250,000 in research costs per year, NIH said.

Letters of intent must be received by Jan. 22, 2011, and applications should be received by Feb. 22 with Sept. 1, 2011, as the earliest anticipated start date.

Now in its early stages, the LINCS program was set up to “develop a ‘library’ of molecular signatures, based on gene expression and other cellular changes that describe the response that different types of cells elicit when exposed to various perturbing agents, including siRNAs and small bioactive molecules.”

According to the NIH, the first phase of the project will focus on large-scale production of perturbation-induced molecular and cellular signatures, computational tool development and integrative data analyses, and integration of existing datasets into the LINCS database among other activities.

More information about the award program can be found here.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.